Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® ▼ (abemaciclib)
What is Verzenios® ▼ (abemaciclib) recommended dosing and administration in patients with metastatic breast cancer?
The recommended dose of abemaciclib is 150 mg twice daily in combination with endocrine therapy.
How Long Should Patients take Abemaciclib?
Patients should take abemaciclib without a treatment pause, as long as they benefit from the therapy or until unacceptable toxicity occurs.1
How Is Abemaciclib Administered?
- take abemaciclib with or without food
- avoid grapefruit or grapefruit juice
- take the doses at the same times every day, and
- swallow the tablet whole.1
When is Abemaciclib Dose Modification Necessary?
Dose modification is recommended based on individual safety and tolerability.
The management of adverse reactions, such as diarrhea, hematologic toxicities, hepatotoxicity, or pneumonitis, may require dose interruption, dose reduction, or both.2
Please find detailed information in the Verzenios Summary of Product Characteristics.1
How is an Abemaciclib Overdose Managed?
Are Dose Modifications Necessary for Patients with Hepatic Impairment
Dose adjustments are only required for patients with severe hepatic impairment (Child-Pugh C). Decrease the dosing frequency to once daily in these patients.
No dose adjustments are necessary for patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment.1
Are Dose Modifications Necessary for Patients with Renal Impairment?
No dose adjustment is required for patients with mild or moderate renal impairment. We have no data in patients with severe impairment or on dialysis.
1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: July 28, 2021